Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma | MicrobiomeTrials
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-09Est. Completion: 2030-01
Enrollment target: 140 participants
Locations
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Guangdong Second People's Hospital, Guangzhou, Guangdong, China
The First Affiliated Hospital Of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The Fifth Affiliated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangdong Medical University, Guangzhou, Guangdong, China
Jiangmen Central Hospital, Jiangmen, Guangdong, China
Wuhan Union Hospital of China, Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
The Affiliated Hospital of QingDao University, Qingdao, Shandong, China
Other microbiome trials you might be interested in